ESMO Congress | Conference

Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer

October 22nd 2018

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Larotrectinib Demonstrates High Response Rate, Durability in NTRK+ Cancers

October 21st 2018

Patients with advanced cancers associated with NTRK gene fusions had an 80% objective response rate with the TRK inhibitor larotrectinib, pooled results from three small trials showed.

Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC

October 21st 2018

The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.

Dr. Andre on the Impact of the SOLAR-1 Findings in Breast Cancer

October 21st 2018

Fabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Radiotherapy Raised to New Standard in Newly Diagnosed Prostate Cancer With Low Metastatic Burden

October 21st 2018

When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.

Dr. Arkenau on Survival Data With TAS-102 in Gastric Cancer

October 21st 2018

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses survival data with TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric cancer at the 2018 ESMO Congress.

Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC

October 21st 2018

The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.

Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer

October 21st 2018

The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.

Alpelisib Combo Nearly Doubles PFS in PIK3CA-Mutant Breast Cancer

October 21st 2018

The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

OS Benefit Confirmed With Palbociclib Combo in Pretreated HR+/HER2- Breast Cancer

October 21st 2018

The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.

RCC Gene Signatures Validated for Treatment Benefit

October 20th 2018

Distinct gene signatures in renal cell carcinoma correlated with improved progression-free survival with immunotherapy or a targeted agent, according to a new analysis of the phase III IMmotion151 trial.

Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial

October 20th 2018

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Atezolizumab Combo Improves PFS in Frontline Metastatic TNBC

October 20th 2018

The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC

October 20th 2018

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

MET, EGFR C797S Linked With Acquired Resistance to Frontline Osimertinib in NSCLC

October 19th 2018

MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant non–small cell lung cancer.

Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma

September 20th 2017

The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.

Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma

September 20th 2017

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.

Dr. Garassino on the PACIFIC Trial for NSCLC

September 20th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).